Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Safety and Efficacy of Oral PIPE-307 As an Adjunctive Treatment in Subjects with Relapsing-Remitting Multiple Sclerosis

Next Previous
Trial Profile

A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Safety and Efficacy of Oral PIPE-307 As an Adjunctive Treatment in Subjects with Relapsing-Remitting Multiple Sclerosis

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 08 Dec 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs PIPE-307 (Primary)
  • Indications Multiple sclerosis
  • Focus Adverse reactions; Proof of concept; Therapeutic Use
  • Acronyms VISTA
  • Sponsors Contineum Therapeutics

Most Recent Events

  • 20 Nov 2025 According to Contineum Therapeutics media release, the Company intends to present the complete dataset at a future medical meeting and to publish full results in a peer-reviewed medical journal.
  • 20 Nov 2025 According to Contineum Therapeutics media release, Primary endpoint has not been met. (Change in binocular 2.5% low contrast letter acuity (LCLA))
  • 20 Nov 2025 Results presented in the Contineum Therapeutics Media Release

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top